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Background: Information on cancer prevalence is either absent or largely unavailable for central European
countries.
Materials and methods: Austria, Germany, The Netherlands, Poland, Slovakia, Slovenia and Switzerland
cover a population of 13 million inhabitants. Cancer registries in these countries supplied incidence and
survival data for 465000 cases of cancer. The prevalence of stomach, colon, rectum, lung, breast, cervix uteri,
corpus uteri and prostate cancer, as well as skin melanoma, Hodgkin’s disease, leukaemia and all malignant
neoplasms combined was estimated for the end of 1992.
Results: A large heterogeneity was observed within central European countries. For all cancers combined,
estimates ranged from 730 per 100000 in Poland (men) to 3350 per 100 000 in Germany (women). Overall
cancer prevalence was the highest in Germany and Switzerland, and the lowest in Poland and Slovenia. In
Slovakia, prevalence was higher than average for men and lower than average for women. This was observed
for almost all ages. As shown by incidence data, breast cancer was the most frequent malignancy among
women in all countries. Among men, prostate cancer was the leading malignancy in Germany, Austria and
Switzerland, and lung cancer was the major cancer in Slovenia, Slovakia and Poland. The Netherlands had a
high prevalence of both prostate and lung cancer. Time-related magnitude of prevalence within each country
and the variability of such proportions across the countries has been estimated and cancer prevalence is given
by time since diagnosis (1 year, 1–5 years, 5–10 years, >10 years) for each site. The weight of 1-year
prevalence (248 per 100000 among men and 253 per 100000 among women) was <15% of total prevalence.
Prevalent cases between 1 and 5 years since diagnosis represented between 22% and 34% of the total pre-
valence. Prevalent cases diagnosed from 5 to 10 years before (335 per 100000 for men and 505 per 100 000 for
women) represented between 17% and 23% of prevalent cancers. Finally, long-term cancer prevalence
(diagnosed >10 years before), reflecting long-term survival, and number of people considered as cured from
cancer were 490 per 100000 for men and 1028 per 100 000 for women, with a range between 26% (The
Netherlands, men) and 50% (Slovakia, women).
Conclusion: It is clear from observing countries in Central Europe, that high cancer prevalence is associated
with well-developed economies. This burden of cancer could be interpreted as a paradoxical effect of better
treatments and thereby survival. It could also be taken as a sign for not being satisfied with the advances in
treating patients diagnosed with cancer, and for supporting more primary prevention.
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Introduction
Cancer incidence and mortality do not fully reflect the magnitude
of cancer. Cancer registries (CRs) in Nordic countries have
already shown the relevance of measuring prevalence for the
“evaluation of the cancer problem” [1]. For many years, preva-
lence figures have only been delivered by CRs collecting data for
a sufficient period of time to provide unbiased estimates. Recent
advances in statistical methods and requirements for updated
public health strategies [2] explain the interest for prevalence
estimations, using incidence and survival figures.
The aim of this work is to estimate the cancer prevalence for
central European countries, as has been done in a comparable
way for other European areas [3]. Austria, Germany, The Nether-
lands, Poland, Slovakia, Slovenia and Switzerland have a
combined population of 13 million inhabitants and present large
disparities in national population coverage by the CRs. In spite of
their geographical contiguity, these countries belong to different
entities, as defined by the World Health Organization: Poland
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and Slovakia are in Eastern Europe; Slovenia is in Southern
Europe; Austria, Germany, The Netherlands and Switzerland are
in Western Europe. Slovenia (2 million inhabitants) and Slovakia
(5.3 million inhabitants), representing 56% of the dataset, have
nationwide tumour registries. In the other registries (totalling
5.8 million inhabitants), available data have a low degree of
coverage within their respective country. One cancer registry
represents 1.7% of the population in Germany (Saarland), 5.7%
in The Netherlands (Eindhoven) and 7.8% in Austria (Tyrol); two
CRs represent 6.2% of the population in Poland (Warsaw and
Cracow) and 11.8% in Switzerland (Basel and Geneva). This
requires caution in attributing to the whole country figures
derived from the corresponding CRs.
As 55% of the population dataset are incident cases from as
early as 1970, it could be assumed that the majority of prevalent
cases in 1992 were diagnosed after the start of the registration
period. However, it might not be a correct assumption for pre-
valent cases from either Slovakia (41% of the dataset), where
registration started in 1980, or Tyrol (5% of the dataset) and
Warsaw (12% of the dataset), where registration started in 1988.
This heterogeneity between data from the registries is also remark-
able when dealing with life-styles, diet habits, cancer incidence
patterns, cancer survival and health care organisations. As a con-
sequence, differences in estimated results could be expected.
Eleven types of cancer have been considered in the analysis:
stomach, colon, rectum, melanoma, breast, uterus, prostate,
Hodgkin’s lymphoma, leukaemia, lung combined with pleura,
and all malignant cancers combined.
Materials and methods
Data
Nine CRs from Austria, Germany, The Netherlands, Poland, Slovakia,
Slovenia and Switzerland, covering a population of 13 million inhabitants,
provided the incidence and survival data needed to estimate prevalence for
these seven countries. More than 465000 incident tumours were registered
and the data collection period ranged from 4 years (1988–1992 for Warsaw in
Poland) to 22 years (1970–1992 for Geneva in Switzerland and Saarland
in Germany). All registries assured follow-up for vital status at least until
31 December 1992, which is the index date for the estimation of prevalence.
All cases recorded by each cancer registry were included in the analysis.
When some information was missing (on average, not more than 1% of the
total number of cases) imputation procedures were adopted [3]. The only
cases excluded from the analysis were death certificate only (DCO) cases and
cases discovered at autopsy, assuming they did not contribute to the burden of
the disease. Cases lost to follow-up were assigned survival probabilities,
estimated from the successful follow-up of patients of the same gender, age
and period of diagnosis.
Observed prevalence represented the number of individuals diagnosed
with cancer and still alive at a certain date. Unfortunately, this definition
excluded cases either diagnosed before the starting date of the CR or those not
registered due to incompleteness. Therefore, the observed prevalence did not
correspond to the actual number of prevalent cases in a population, as some of
them, still alive, may have escaped cancer registration. A correction factor
named completeness index was used for correcting these estimates of pre-
valence figures. This index is derived from our knowledge of cancer type
specific incidence and survival [4].
The age structure of the populations under observation was slightly differ-
ent. In Slovakia and Austria, the age group 0–44 years represented more than
two-thirds of the male population (72% and 70%, respectively), but only 63%
in Switzerland and 62% in Germany. Among women, we observed a similar
contrast between the highest (Slovakia 66% and Austria 64%) and the lowest
figures (Switzerland 57% and Germany 56%). For both genders, the popula-
tion aged >65 years represented <20% in all countries, ranging between 8%
(Slovenia, men) and 19% (Germany, women).
Calculation of prevalence
Observed prevalence was computed on the basis of the longest period of data
available from each registry, by means of the PREVAL method [5, 6]. This
method basically consists of collecting information from all incident cases
over the period considered by the cancer registration, and following the
patients throughout their life. The information on age and time since
diagnosis was updated according to the life status of the patients known from
the CRs.
Tables with number and proportion of prevalent cases in the populations
covered by each participating CR were sent to the registries for checking and
information. Registry-specific prevalence data were finally combined to
provide prevalence numbers and proportions at country level.
Completeness index
The adjustment applied by the completeness index was derived from our
knowledge of incidence and survival features of each cancer site [4]. The
index varied between 0 and 1, depending on the adjustment introduced in the
prevalence observed by the registry. Values close to 0 indicated a short
observation period and a large correction applied to the observed prevalence.
Values close to 1 indicated a slight correction. Details of the method used for
the estimation of completeness index, have been reported in previous papers
[4, 5]. A common set of parameters was used for the estimation of complete-
ness index in every registry considered in this study. However, relative
survival varied to some extent between registries, in each country considered
here. As relative survival affects prevalence, a relative death ratio specific for
each registry was considered in order to increase the precision in the estima-
tion of completeness index.
The completeness index was near 1 for registries with longer follow-up, for
cancer sites that occurred mainly in the elderly, and for those registries with
low survival rates, because worse prognosis leads to a restricted number of
long-term survivors. In Geneva and Saarland, the two registries with the
longest follow-up period (23 years), completeness of observed prevalence
ranged from 0.88 and 0.87 for cancer of corpus uteri to 1 for cancer of the
prostate and cervix uteri, and Hodgkin’s disease. The corresponding values
for the Warsaw and Tyrol registries, which had the shortest period of follow-
up (5 years) were 0.31 and 0.32 for corpus uteri, 0.67 and 0.78 for prostate,
respectively, and 0.42 for cervix uteri and 0.38 for Hodgkin’s disease for both
registries.
Average prevalence was estimated for all sites and for the seven registries
combined. As figures for The Netherlands were close to these averages, we
used the Dutch prevalence as reference for observing heterogeneity within
our dataset through a prevalence ratio (PR).
Results
Among the seven countries, the mean prevalence estimated for
all cancers combined was 1565 per 100000 persons for men and
2413 per 100000 persons for women, similar to the prevalence
estimated for all 17 European countries combined (1570 for men
and 2490 for women). Table 1 presents cancer prevalence in each
of the seven populations by age group, for men and women,
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Table 1. Total prevalence by country, age class, gender and cancer site. Proportions per 100000 persons
The Netherlands Germany Austria Switzerland
0–44 45–64 65+ All ages 0–44 45–64 65+ All ages 0–44 45–64 65+ All ages 0–44 45–64 65+ All ages
Men
Stomach 3.5 98.4 431.2 63.6 5.6 134.0 626.8 107.5 6.9 150.6 847.2 115.0 4.6 82.6 310.6 61.4
Colon 10.6 207.9 1114.2 154.9 11.2 231.0 1232.2 202.7 6.2 151.1 984.5 127.4 3.4 169.0 1151.4 183.4
Rectum 3.8 158.4 714.2 103.0 4.4 194.3 944.2 157.3 2.6 138.1 477.7 75.2 6.3 116.9 769.3 126.1
Lung 3.3 276.5 1468.0 197.4 5.6 246.5 907.4 168.0 5.7 201.5 610.0 103.1 6.4 215.0 721.6 145.8
Melanoma of skin 18.7 102.5 136.4 48.4 20.9 111.7 213.7 66.1 40.7 240.3 399.0 116.2 35.0 199.7 491.1 132.1
Prostate 0.0 119.0 1895.7 197.7 0.0 163.9 2606.5 327.6 0.0 196.0 3189.8 336.4 0.0 122.6 3154.0 408.4
Hodgkin’s diseasea 17.3 28.2 21.5 20.2 23.0 32.2 28.6 26.1 23.5 50.0 34.3 30.1 21.9 31.5 32.1 25.6
Leukaemia 16.5 45.1 112.5 31.6 21.8 56.3 162.1 46.2 30.2 75.2 140.1 49.9 16.2 76.1 291.5 64.6
All malignant neoplasmsb 252.0 1910.0 8848.8 1403.6 379.8 2681.9 11221.2 2173.5 405.9 2512.9 12320.7 1954.2 371.1 2268.8 10448.7 2066.0
Women
Stomach 2.4 40.5 246.0 42.8 6.6 62.2 352.5 85.4 5.2 97.1 569.7 111.0 3.4 35.4 178.4 42.8
Colon 13.1 186.1 1020.0 183.5 18.9 221.2 1096.3 271.8 7.6 160.4 712.8 147.6 6.0 136.9 866.4 193.2
Rectum 1.0 125.8 512.2 95.9 5.6 135.1 638.0 156.8 2.3 105.5 393.1 83.7 5.0 112.2 536.8 127.4
Lung 3.1 79.3 101.1 33.1 2.3 51.3 100.1 33.1 3.9 68.9 111.1 33.9 3.4 71.6 144.0 45.9
Melanoma 48.2 231.4 165.8 105.0 31.8 168.3 234.6 104.6 86.7 430.7 475.4 217.9 53.4 285.8 393.8 173.5
Breast 100.2 1824.3 3227.5 898.1 106.9 1485.8 3435.7 1081.7 60.8 1355.6 2834.8 755.9 97.4 1867.7 3577.0 1170.6
Cervix uteria 36.0 97.5 155.8 65.5 56.1 207.4 284.5 137.5 68.2 432.1 349.5 187.0 23.6 124.7 151.2 72.2
Corpus uteri 1.7 262.8 926.9 181.4 6.7 271.5 1452.5 344.3 5.5 272.4 1136.8 234.7 4.3 236.5 1351.1 304.3
Hodgkin’s diseasea 17.3 18.3 13.4 17.0 22.6 14.4 15.9 19.2 22.5 33.2 13.4 23.4 16.7 20.0 15.8 17.4
Leukaemia 13.7 31.9 81.1 26.6 21.2 40.2 69.0 35.0 15.1 47.1 80.3 31.8 12.6 36.2 122.5 38.3
All malignant neoplasmsb 411.5 3949.0 9053.4 2338.8 477.0 3825.8 11282.1 3351.7 578.8 4422.5 10341.7 2876.7 387.4 4005.5 9989.0 3026.1
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Table 1. (Continued)
aFifteen-year prevalence.
bAll neoplasms excluding non-melanoma skin cancer.
Slovenia Slovakia Poland All European countries (n = 17)
0–44 45–64 65+ All ages 0–44 45–64 65+ All ages 0–44 45–64 65+ All ages 0–44 45–64 65+ All ages
Men
Stomach 5.5 113.0 397.5 61.5 3.7 122.8 712.1 90.8 2.7 62.5 175.9 35.2 3.0 89.5 376.5 67.8
Colon 4.2 116.5 450.4 65.6 6.6 162.9 707.1 99.9 2.5 69.1 253.8 44.7 6.0 151.6 819.4 137.4
Rectum 3.5 142.7 470.0 72.7 4.1 171.5 734.0 102.3 1.0 68.3 203.5 38.3 3.2 123.2 599.0 102.4
Lung 7.5 262.1 672.0 118.9 6.3 398.6 1390.4 206.5 5.5 216.2 424.5 100.0 3.8 201.5 791.5 144.1
Melanoma of skin 8.6 57.8 112.7 28.2 9.4 71.2 155.3 34.4 6.4 43.2 67.9 21.7 15.9 98.8 163.0 52.6
Prostate 0.0 51.3 888.3 82.9 0.3 69.5 1244.7 126.9 0.3 35.0 341.8 44.1 0.2 80.1 1555.5 206.6
Hodgkin’s diseasea 20.8 29.1 15.2 22.2 18.6 20.1 27.5 19.7 17.0 24.0 17.0 18.7 25.0 32.6 21.9 26.3
Leukaemia 15.7 40.7 127.3 30.4 17.1 49.4 226.0 42.3 11.4 17.0 35.4 15.2 20.4 41.3 139.1 39.5
All malignant neoplasmsb 252.9 1725.8 6188.3 1064.7 259.0 2343.5 10218.7 1560.6 176.6 1180.0 3162.8 729.5 298.4 1908.6 7784.5 1570.6
Women
Stomach 4.9 71.2 266.8 57.5 2.9 62.5 440.8 72.4 2.0 30.6 93.2 23.5 2.2 42.4 202.7 46.6
Colon 4.9 89.0 312.8 68.1 6.2 123.7 485.6 93.1 3.0 63.2 176.0 45.4 7.2 147.1 717.2 163.9
Rectum 2.8 120.7 384.0 84.2 4.2 114.8 507.5 92.8 2.6 69.2 161.9 44.5 3.0 96.0 407.7 95.3
Lung 1.5 36.1 60.5 17.8 2.0 40.3 141.5 28.1 2.9 57.3 103.9 32.6 2.2 59.7 166.1 44.2
Melanoma 23.5 130.7 155.8 66.9 18.2 122.3 194.3 62.6 12.3 74.3 84.9 39.5 34.6 182.8 251.8 106.5
Breast 68.9 1004.0 1570.0 497.1 49.4 793.1 1391.7 377.7 67.3 814.5 1138.7 425.6 85.8 1530.3 2599.8 855.6
Cervix uteria 65.5 226.3 254.6 129.3 74.5 358.2 333.0 166.5 55.0 350.5 273.6 164.6 57.9 228.4 206.6 122.7
Corpus uteri 3.5 366.8 1161.8 251.9 8.1 420.4 1292.8 260.8 7.8 345.4 800.1 217.9 5.2 265.6 846.0 212.3
Hodgkin’s diseasea 16.9 11.9 12.6 15.1 18.7 15.2 16.0 17.6 18.3 16.7 5.7 15.9 21.4 18.2 13.6 19.3
Leukaemia 14.7 32.2 104.3 31.5 15.8 32.7 119.6 32.9 9.3 11.1 34.5 13.7 18.3 28.3 82.3 31.9
All malignant neoplasmsb 375.9 3068.4 6022.6 1797.8 369.0 3181.4 8023.5 1947.8 354.6 2706.8 4164.3 1550.8 441.7 3709.2 7860.3 2490.0
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respectively, and for all European countries included in the
EUROPREVAL study combined (n = 17) (given for reference).
Figures 1 and 2 summarise the heterogeneity observed within
central European countries: overall, cancer prevalence was
highest in Germany and Switzerland, and lowest in Poland and
Slovenia. In Slovakia, prevalence is higher than average for men,
and lower than average for women. This was observed for almost
all ages.
Breast cancer is the most frequent malignancy among women
in all countries, with the highest prevalence found in Switzerland
(1170 cases for 100000 persons). Among men, prostate cancer is
the leading malignancy in Germany, Austria and Switzerland
(the highest prevalence proportion is 408 per 100000) and lung
cancer is the commonest cancer in Slovenia and Slovakia (the
highest prevalence proportion is 206 per 100000) and Poland.
The Netherlands has a high prevalence for prostate and lung
cancer (198 per 100000 for both).
Regarding cancer prevalence by time since diagnosis (Tables 2
and 3), two issues were considered: the time-related magnitude of
prevalence within each country and the variability of such propor-
tions across the countries. One-year prevalence consisted of
cancer patients that were likely to be under primary treatment and
therefore required more resources from the health-care system.
For all malignancies combined, the mean proportion of 1-year
prevalence for the central European countries was 248 per 100000
among men, representing 15–20% of total cancer prevalence.
The mean proportion per site varied from 10 to 20 per 100000 for
all sites, except for lung (40.4), prostate (44.4), Hodgkin’s disease
(2.2) and leukaemia (5.8). Among women, the mean proportion
of 1-year prevalence for the central European countries was 253
per 100000, representing ∼10% of cancer prevalence. The range
was similar: from 10 to 20 per 100000 for all sites except breast
(83.1), Hodgkin’s disease (1.7) and leukaemia (4.9).
Prevalent cases between 1 and 5 years since diagnosis were
more likely to undergo follow-up procedures for recurrence and
adverse reactions. The magnitude of this prevalence was also a
useful indicator of the patients’ demand for health-care facilities
and of its impact on the medical system and health infrastructure.
All sites combined, the mean proportion for the central European
countries was 491 per 100000 for men and 626 per 100000 for
women, with a range of proportion of the total prevalence
between 22% and 28% for women, and 24% and 34% for men.
Prevalent cases diagnosed from 5 to 10 years previously repre-
sent a component of patients with a lower demand for frequent
control examinations. All sites combined, mean proportions were
335 per 100000 for men and 505 per 100000 for women, with a
range of proportion of the total prevalence between 17% and 23%
for both genders.
Finally, long-term cancer prevalence (diagnosed >10 years
before) reflected long-term survival and proportion of people
considered as cured from cancer. All sites combined, mean pro-
portions were 490 per 100 000 for men and 1028 per 100 000 for
women, with a range of proportion between 26% (The Nether-
lands, men) and 50% (Slovakia, women).
Age was an important factor influencing accuracy and timing
of diagnosis, as well as effectiveness of treatment and prognosis.
Prevalence of cancer in the elderly (Tables 4 and 5) represented
an increasing load for the community, due to frequently associ-
ated comorbidity and disability factors. For all cancers combined,
people aged ≥65 years accounted for between 43% (Poland) and
72% (Switzerland) of cancer prevalence. The proportion of elderly
patients was highest for prostate cancer (males; range from 80%
in Poland to 92% in Switzerland) and lowest for Hodgkin’s
disease, with <40% in all countries except Slovakia (49%).
Discussion
The methods for solving the main methodological problems are
described extensively elsewhere [7, 8]. In addition, we can focus
on some specific issues.
Figure 1. Prevalence rate ratios in men for all malignant neoplasms.
Figure 2. Prevalence rate ratios in women for all maligant neoplasms.
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Completeness index
There is an apparent contradiction between the high proportion
lost to follow-up in Geneva (5.4%), compared with all the others
(<2%) except Cracow (4.7%), and the completeness index for
which Geneva has, for all cancer sites, a value near to one.
Geneva has a very peculiar situation: the population is actively
monitored and the administration knows exactly the dates of
arrival and departure through the regime of residency permits.
The Geneva CR has on-line access to this population data and
traces patients for active follow-up twice a year. Thus, the exact
number of prevalent patients is known at any time (index of
completeness close to 1). However, the high proportion of ‘lost to
follow-up’ simply reflects the fact that the number of foreigners
Table 2. Prevalence by time since diagnosis, site and country for men (per 100000)
aAll neoplasms excluding non-melanoma skin cancer.
Cancer site Time since 
diagnosis 
(years)
The 
Netherlands
Germany Austria Switzerland Slovenia Slovakia Poland Central 
Europe
Stomach 1 11.4 14.0 19.2 10.7 15.1 13.6 9.7 13.4
1–5 15.0 25.5 32.7 16.3 19.2 17.9 8.0 19.2
5–10 13.7 23.4 22.4 10.7 11.3 16.8 6.8 15.0
>10 23.5 44.6 40.8 23.7 15.9 42.6 10.7 28.8
Colon 1 23.6 33.1 22.1 22.4 14.8 15.3 12.0 20.5
1–5 54.9 63.8 47.1 64.5 24.3 32.9 13.1 43.0
5–10 40.6 49.4 29.9 47.5 12.3 22.3 9.9 30.3
>10 35.8 56.4 28.3 49.0 14.3 29.4 9.8 31.8
Rectum 1 16.5 22.2 14.4 20.8 15.7 17.0 10.5 16.7
1–5 42.3 46.9 27.5 47.0 30.3 34.7 13.3 34.6
5–10 23.2 32.7 17.2 29.2 15.2 20.9 8.0 20.9
>10 21.0 55.5 16.1 29.0 11.5 29.8 6.5 24.2
Lung 1 53.4 45.7 31.1 36.8 39.0 37.7 39.0 40.4
1–5 66.3 47.5 33.6 45.2 37.1 38.3 28.9 42.4
5–10 30.5 24.1 14.2 26.7 13.4 37.3 10.3 22.4
>10 47.2 50.6 24.2 37.1 29.4 93.3 21.8 43.4
Melanoma of skin 1 7.7 7.0 16.0 16.8 5.7 4.6 4.3 8.9
1–5 18.7 23.5 47.4 43.4 10.5 11.7 8.6 23.4
5–10 12.0 19.8 31.2 38.4 7.1 8.2 5.2 17.4
>10 10.0 15.7 21.5 33.5 4.8 9.8 3.5 14.1
Prostate 1 43.1 56.8 78.8 76.5 21.6 20.3 13.4 44.4
1–5 92.9 115.6 145.4 181.4 41.0 50.0 20.0 92.3
5–10 41.4 76.7 78.7 101.6 15.6 31.3 8.5 50.5
>10 20.2 78.5 33.5 48.9 4.7 25.3 2.3 30.5
Hodgkin’s disease 1 2.6 2.1 3.5 1.8 1.9 2.0 1.6 2.2
1–5 6.4 9.5 9.3 7.9 7.7 6.4 6.2 7.6
5–10 5.8 8.6 9.3 9.1 6.6 5.5 6.0 7.3
10–15 5.4 5.8 8.0 6.8 6.0 5.8 4.9 6.1
Leukaemia 1 5.4 4.3 5.8 10.7 5.9 5.6 2.9 5.8
1–5 12.2 19.8 21.8 23.9 12.3 13.8 5.4 15.6
5–10 7.1 14.0 11.3 19.8 7.4 9.3 3.8 10.4
>10 7.0 8.1 11.1 10.2 4.7 13.5 3.1 8.2
Malignant neoplasmsa 1 249.4 322.1 292.1 305.2 202.2 203.1 165.2 248.5
1–5 479.0 651.1 641.5 710.7 339.8 386.3 229.3 491.1
5–10 309.5 504.6 444.9 464.0 194.1 296.2 131.7 335.0
>10 365.7 695.7 575.7 586.2 328.6 675.1 203.2 490.0
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Table 3. Prevalence by time since diagnosis, site and country for women (per 100 000)
aAll neoplasms excluding non-melanoma skin cancer.
Cancer site Time since 
diagnosis 
(years)
The 
Netherlands
Germany Austria Switzerland Slovenia Slovakia Poland Central 
Europe
Stomach 1 8.7 10.9 19.8 6.8 7.3 7.2 4.8 9.4
1–5 10.9 20.9 34.4 13.4 13.9 11.4 5.1 15.7
5–10 7.6 23.5 22.9 7.3 10.4 11.3 3.7 12.4
>10 15.5 30.1 33.8 15.4 25.8 42.4 9.9 24.7
Colon 1 25.8 36.4 20.7 26.7 12.2 13.5 10.1 20.8
1–5 62.2 77.6 53.6 62.6 23.4 27.8 13.3 45.8
5–10 45.4 74.7 38.0 47.4 15.3 19.0 10.6 35.8
>10 50.1 83.1 35.3 56.5 17.3 32.7 11.4 40.9
Rectum 1 14.6 20.7 10.7 21.8 12.0 12.0 8.7 14.4
1–5 31.2 43.1 29.8 34.0 24.1 24.3 10.6 28.2
5–10 22.1 32.3 19.5 27.2 15.5 15.9 9.0 20.2
>10 28.0 60.7 23.7 44.4 32.6 40.6 16.2 35.2
Lung 1 11.1 8.1 9.4 14.5 7.5 6.0 13.8 10.1
1–5 10.3 10.9 12.8 15.2 7.0 6.5 8.2 10.1
5–10 6.1 5.7 5.7 7.0 1.7 6.1 6.2 5.1
>10 5.6 8.4 6.0 9.1 1.7 9.6 4.4 6.4
Melanoma of skin 1 11.4 10.4 18.6 13.6 7.2 5.7 3.8 10.1
1–5 32.5 27.5 67.3 48.1 21.2 15.0 11.2 31.8
5–10 24.9 29.8 55.9 46.9 13.1 13.6 9.8 27.7
>10 36.2 37.0 76.1 64.9 25.3 28.3 14.7 40.4
Breast 1 99.6 103.7 91.3 118.9 63.0 48.4 57.1 83.1
1–5 301.8 302.4 246.6 389.7 185.8 123.5 154.7 243.5
5–10 236.5 255.8 210.9 295.9 122.9 84.8 114.0 188.7
>10 260.2 419.8 207.1 366.2 125.4 121.0 99.8 228.5
Cervix uteri 1 9.2 13.5 14.9 5.9 15.6 19.5 20.1 14.1
1–5 23.8 42.5 63.0 21.8 42.6 51.4 51.3 42.4
5–10 18.8 40.8 59.0 24.9 40.1 46.9 50.9 40.2
10–15 13.8 40.7 50.1 19.7 31.0 48.7 42.3 35.2
Corpus uteri 1 12.2 24.4 17.7 17.1 19.6 20.6 18.6 18.6
1–5 43.0 70.1 56.6 60.0 55.3 55.4 52.9 56.2
5–10 47.2 74.3 55.8 73.1 50.7 49.5 49.1 57.1
>10 79.0 175.5 104.6 154.0 126.4 135.4 97.3 124.6
Hodgkin’s disease 1 2.0 2.6 2.4 0.9 1.1 1.2 1.4 1.7
1–5 4.6 5.7 6.4 4.9 5.6 5.7 5.3 5.5
5–10 5.5 7.0 7.4 7.0 4.3 5.3 4.9 5.9
10–15 5.0 3.9 7.1 4.5 4.1 5.4 4.3 4.9
Leukaemia 1 5.2 5.2 5.5 7.0 5.2 3.6 2.4 4.9
1–5 7.6 14.0 13.7 12.4 12.7 10.3 5.0 10.8
5–10 7.0 8.3 7.3 12.2 7.2 8.0 3.4 7.6
>10 6.7 7.4 5.3 6.6 6.4 11.0 2.9 6.6
Malignant neoplasmsa 1 259.4 321.3 300.5 301.0 206.8 188.6 196.8 253.5
1–5 640.5 791.9 801.3 811.4 495.4 438.6 406.6 626.5
5–10 511.9 711.3 640.4 660.2 348.6 343.6 317.8 504.8
>10 927.0 1527.3 1134.5 1253.4 747.0 977.0 629.6 1028.0
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normally qualified as residents leave Geneva, to return to their
country of origin, at the end of their life [9]. In the current process
of estimating prevalence through a mathematical model, patients
that have left Geneva continue to be considered alive, and con-
tribute therefore to an overestimation of survival. This (late)
migration phenomenon is medically important in Geneva, a city
of international organisations with a high proportion of foreign-
ers. In this situation, the overestimation of survival could bias the
overall dataset and, therefore, Geneva data have not been used for
the validation of prevalence modelling.
Variability within the central European countries
The dataset, arbitrarily defined as ‘central European’, combines
countries with different demographic situations. Age distribution
by gender is similar within each country, and figures with both
genders combined can be used to define ‘young’ countries,
(Slovakia, Austria, The Netherlands, Slovenia) with more than
two-thirds of the population aged 0–44 years and ‘old’ countries
(Poland, Switzerland, Germany) with less than two-thirds of the
population aged 0–44 years. The proportion of youngest age
Table 4. Proportion (%) of mature (45–64 years) and elderly (65+ years) men and women among cancer prevalent cases
aAll neoplasms excluding non-melanoma skin cancer.
The 
Netherlands
Germany Austria Switzerland Slovenia Slovakia Poland
45–64 years
Stomach 27.0 28.5 21.4 33.6 25.7 16.5 23.9
Colon 21.0 29.6 19.9 29.9 18.5 21.9 25.6
Rectum 24.1 39.9 22.0 36.7 20.6 22.0 27.4
Lung 30.6 51.8 31.5 39.6 34.3 41.0 36.5
Melanoma of skin 37.7 52.3 34.3 55.8 36.3 39.0 42.2
Hodgkin’s disease 42.5 37.1 48.6 44.1 33.5 24.1 46.4
Leukaemia 20.4 39.2 25.0 34.0 24.9 22.5 24.8
Malignant neoplasmsa 32.1 37.5 24.6 40.1 28.2 32.7 31.4
65+ years
Stomach 52.0 88.3 58.0 90.9 49.7 66.8 53.2
Colon 56.4 87.6 59.5 94.2 58.1 61.9 52.1
Rectum 54.4 79.2 58.9 90.0 55.4 61.2 50.9
Lung 49.9 64.4 48.6 86.2 43.6 45.3 43.6
Melanoma of skin 30.0 39.5 32.7 30.2 31.5 34.8 28.1
Hodgkin’s disease 17.9 25.2 17.0 25.5 38.0 48.5 25.3
Leukaemia 29.9 37.4 31.3 48.5 41.3 44.0 33.7
Malignant neoplasmsa 41.3 67.8 50.2 72.2 44.5 46.6 42.8
Table 5. Proportion (%) of mature (45–64 years) and elderly (65+ years) patients among cancer prevalent cases, for 
gender-specific sites
The 
Netherlands
Germany Austria Switzerland Slovenia Slovakia Poland
45–64 years
Prostate 13.7 13.3 12.4 7.8 14.1 10.3 19.2
Breast 46.0 36.5 37.3 40.6 46.2 43.1 48.8
Cervix uteri 33.7 40.1 48.0 44.0 40.0 44.1 54.3
Corpus uteri 32.8 21.0 24.1 19.8 33.3 33.1 40.5
65+ years
Prostate 86.3 86.7 87.6 92.2 85.9 89.5 80.4
Breast 46.9 59.2 57.6 54.7 45.1 48.2 41.9
Cervix uteri 31.0 38.6 28.7 37.5 28.1 26.2 26.0
Corpus uteri 66.6 78.7 74.4 79.4 65.8 64.9 57.4
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group ranges from 59% (Germany) to 69% (Slovakia). In addi-
tion, taking into account unequal age distributions and the risk of
mortality observed for the whole population in each country
(including non-cancer patients), we also observe large differ-
ences in cancer survival [10]. All cancers combined, the 5-year
age-adjusted relative survival (AARS) ranges from 19% (Poland)
to 45% (Austria) for men, and from 33% (Poland) to 55%
(Switzerland) for women, reflecting the discrepancies in health-
care systems. Illustrating this unbalanced situation, the 5-year
AARS for several sites (digestive tract, prostate, all sites com-
bined) in the countries having the richer economies (Germany,
The Netherlands, Switzerland) are higher than the 1-year AARS
for some other countries (Poland, Slovakia), reflecting the
differences between countries in access to care facilities, avail-
ability of modern investigation techniques and capacity for early
diagnosis.
Burden of cancer and priorities
Prevalence, which results from the combined effects of the age
structure of the population, age-specific incidence and quality of
care, demonstrating the actual burden of disease in a different
way than incidence alone does. If short-term prevalence can be
assumed to be close to incidence figures, long-term prevalence is
obviously linked with the efficiency of the health-care system
and its capacity to provide long-term survival.
Stomach. Slovenia, Austria, Slovakia and Poland have the four
highest incidence age-standardised (European) rates, ranging
from 19 to 26 per 100000 per year [11]. Within this group, the
highest prevalence for men and women is only found in Austria
(115 and 111 per 100000 for all ages); much higher (up to
6.7 times) than the country having the lowest prevalence (Poland).
It seems clear that even if burden of disease, in terms of risk
(incidence rates), is similar for these four countries, the actual
burden, in terms of proportion of patients under treatment and
follow-up, is higher in Austria, due to better survival. Five-year
AARS in Austria, both genders combined, is 27%, and the 1-year
and 5-year survival rates in Poland are 24% and 9%, respectively
[10].
Colon. Countries with the highest overall risk (Germany,
Switzerland, The Netherlands and Austria) have the highest
overall prevalence proportions for men and women. Burden of
disease is even accentuated by a much better survival in these
countries. For example, 5-year AARS figures in The Netherlands
for men (59%) or for women (56%) are better than the 1-year
AARS figures in Slovakia (54% and 54%, respectively) and
Slovenia (50% and 54%, respectively). Another example, the
1-year survival rate in Poland for men and women (43%) is worse
than the 5-year survival rates in Austria, Switzerland and
Germany for both genders. However, one can observe some par-
ticularities in prevalence by age group (through the prevalence
ratios), within the group of high incidence–high prevalence
countries. Switzerland and Austria have a prevalence lower than
The Netherlands and Germany for young people (age <65 years).
This might be due to different attitudes towards colon cancer
prevention through polyp detection, but this hypothesis needs to
be investigated.
Lung. This cancer site is characterised by poor survival every-
where, i.e. <30% after 1 year, and ≤10% after 5 years. This means
that health-care system and treatment do not have a great impact
on prevalence, mainly related to age-specific incidence and
demographic structure. Illustrating this, the prevalence ratios by
period since diagnosis decrease with time in all countries except
in Slovakia, where prevalence after 10 years is 2.5× prevalence
at 1 year after diagnosis for men (93.3 compared with 37.7 per
100000), and 1.6× for women (9.6 compared with 6.0 per
100000). This exception could be explained by one of the next
two proposals. First, because Slovakia has one of the highest inci-
dence rates among men (79 per 100000), the highest proportion
of young people aged 0–44 years (72% among men and 66%
among women) and the best 5-year AASR [10]. Secondly,
because Slovakia has a passive follow-up system producing a
number of lost cases that have been (wrongly) considered as alive
and therefore led to overestimated prevalence counts. Both
explanations could be right.
Breast and prostate. High prevalence of breast and prostate
cancers are indeed the triple effect of high incidence, demo-
graphic factors (age distribution skewed toward old age), and
good survival, within the same countries, especially Switzerland,
Germany, The Netherlands and Austria. In addition, the observed
decrease of mortality from breast cancer due to screening pro-
grammes (The Netherlands) should reinforce this trend for high
prevalence figures in future.
Cervix. In countries with an efficient health-care system, early
stage at diagnosis and efficient treatment explain the good survival
figures, such as 1-year and 5-year AARS rates being 90% and
67% in Switzerland, versus 76% and 51% in Poland, respectively
[10], and high prevalence should be observed. However, a para-
doxical situation in such countries is that they could also be con-
sidered at low risk (and with a small burden of disease), simply
because they benefit from a good level of secondary prevention.
In these cases, the high proportion of cancer in situ is lowering
the incidence of malignant tumours, and thereby lowering the
prevalence, which is estimated on the basis of invasive tumours.
However, the impact of this prevention is generally less marked
after the menopause than before, and this leads to an increase in
the prevalence proportions among elderly women, mainly for
long-term prevalence. In these countries we also observe the
lowest incidence and the lowest prevalence, but the highest pro-
portions of elderly among prevalent cases.
Skin melanoma. The range of incidence rates is wide, about 4×
higher in countries at very high risk (Austria and Switzerland)
compared with countries at low risk (Slovenia, Slovakia and
Poland), and the range in prevalence estimates is on the same
scale. This observation is not surprising, with 5-year survival
figures much better for those countries at high risk (AARS >80%)
than for countries at low risk (AARS <70% among women and
<55% among men).
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Conclusion
Observing countries in central Europe, high cancer prevalence is
associated with well-developed economies. Several parameters
are concordant for explaining this phenomenon, such as higher
proportion of elderly people, lower general mortality, more
frequent early detection and high expenditure on health care. This
increased burden of cancer could be interpreted as a paradoxical
effect of improving treatments and thereby survival. This could
also be an indication for not only being satisfied with the
advances in treating patients diagnosed with cancer, but also for
supporting more primary prevention.
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